$AVRW has provided positive guidance for the upcoming Q3 report back in August. Sales of the increasingly popular Seratopical product line are on an improving growth curve. Just a matter of time for this trend to be reflected in a matching stock pps rise. Could be quite rapid too if shorts have to scramble to cover and fight each other for shares. -------------------------------------------------------------------------------------------------------- ...we are encouraged by the early results and accelerating sales heading into the third quarter, which reaffirms the improving overall trajectory of the business. As mentioned in our first quarter earnings announcement, the proceeds from the July 2022 asset sale allowed us to invest in the future of the Company, but the delay in receiving the balance of the proceeds versus our expectations had a negative impact on our second quarter performance. Our margin expansion initiatives continue to deliver results, and we are moving forward with our efforts to further reduce SG&A expenses and to maximize operating leverage.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.